Therefore , the use of CD169 macrophage targeting cancer therapies requires careful consideration of pitfalls .
Not only that , erythropoietic activity was severely impaired .
The use of CD169 macrophage targeting cancer therapies requires careful consideration of pitfalls .
Not only that , erythropoietic activity was severely impaired .